NSE:WOCKPHARMA (India)
Â
Shs Dematerialised
₹
2,187.3
+13.8 (+0.67%)
Sep 21
Business Description
Wockhardt Ltd
SIC : 2834
ISIN : INE049B01025
Share Class Description:
NSE:WOCKPHARMA: Shs DematerialisedTotal Employee Number:
4,084Compare
Compare
Traded in other countries / regions
532300.India Index Membership
NIFTY 500 IPO Date
2000-02-23Description
Wockhardt Ltd is an Indian pharmaceutical and biotechnology company engaged in the development, manufacture, and marketing of generic and branded pharmaceutical products. Its portfolio spans formulations, active pharmaceutical ingredients, and biopharmaceuticals, with therapeutic focus areas including anti-infectives, cardiology, diabetes, pain management, and neurology. The company operates manufacturing and research facilities in India and the United Kingdom, and sells its products across India, the United States, Europe, and other international markets. Wockhardt also provides contract manufacturing and research services. Revenue is generated primarily through the sale of pharmaceutical formulations and APIs, with a significant share derived from international markets, particularly Europe and the United States, alongside a branded generics business in India. The company's only reportable business segment is its pharmaceutical business.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.28 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.45 | |||||
Debt-to-EBITDA | 2.47 | |||||
Interest Coverage | 2.26 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 7.28 | |||||
Beneish M-Score | -2.56 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.6 | |||||
3-Year Book Growth Rate | 9.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.8 | |||||
9-Day RSI | 52.63 | |||||
14-Day RSI | 54.55 | |||||
3-1 Month Momentum % | -6.5 | |||||
6-1 Month Momentum % | 53 | |||||
12-1 Month Momentum % | 21.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.66 | |||||
Quick Ratio | 1.12 | |||||
Cash Ratio | 0.39 | |||||
Days Inventory | 253.78 | |||||
Days Sales Outstanding | 60.94 | |||||
Days Payable | 178.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.1 | |||||
Shareholder Yield % | -0.46 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 66.67 | |||||
Operating Margin % | 13.78 | |||||
Net Margin % | 11.48 | |||||
EBITDA Margin % | 25.42 | |||||
FCF Margin % | 1.8 | |||||
OCF Margin % | 5.61 | |||||
ROE % | 8.85 | |||||
ROA % | 4.85 | |||||
ROIC % | 6.21 | |||||
3-Year ROIIC % | -126.03 | |||||
ROC (Joel Greenblatt) % | 22.01 | |||||
ROCE % | 10.26 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 82.89 | |||||
PE Ratio without NRI | 84.96 | |||||
PS Ratio | 9.51 | |||||
PB Ratio | 6.87 | |||||
Price-to-Tangible-Book | 16.48 | |||||
Price-to-Free-Cash-Flow | 1305.68 | |||||
Price-to-Operating-Cash-Flow | 87.07 | |||||
EV-to-EBIT | 52.73 | |||||
EV-to-EBITDA | 39.58 | |||||
EV-to-Revenue | 10.06 | |||||
EV-to-FCF | 1437.96 | |||||
Price-to-GF-Value | 1.4 | |||||
Price-to-Projected-FCF | 9.19 | |||||
Price-to-Median-PS-Value | 5.38 | |||||
Price-to-Graham-Number | 9.12 | |||||
Earnings Yield (Greenblatt) % | 1.91 | |||||
FCF Yield % | 0.07 | |||||
Forward Rate of Return (Yacktman) % | -32.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Wockhardt Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 35,640 | ||
| EPS (TTM) (₹) | 25.17 | ||
| Beta | 1.6898 | ||
| 3-Year Sharpe Ratio | 1.33 | ||
| 3-Year Sortino Ratio | 3.7 | ||
| Volatility % | 58.24 | ||
| 14-Day RSI | 54.55 | ||
| 14-Day ATR (₹) | 78.93521 | ||
| 20-Day SMA (₹) | 2040.195 | ||
| 12-1 Month Momentum % | 21.84 | ||
| 52-Week Range (₹) | 1086.7 - 2422.3 | ||
| Shares Outstanding (Mil) | 162.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Wockhardt Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Wockhardt Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Wockhardt Ltd Frequently Asked Questions
What is Wockhardt Ltd(NSE:WOCKPHARMA)'s stock price today?
The current price of NSE:WOCKPHARMA is ₹2187.30. The 52 week high of NSE:WOCKPHARMA is ₹2422.30 and 52 week low is ₹1086.70.
When is next earnings date of Wockhardt Ltd(NSE:WOCKPHARMA)?
The next earnings date of Wockhardt Ltd(NSE:WOCKPHARMA) is .
Does Wockhardt Ltd(NSE:WOCKPHARMA) pay dividends? If so, how much?
Wockhardt Ltd(NSE:WOCKPHARMA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers